IP Library Granted Patent US 10,112,903
Granted Patent B2
US 10,112,903 · App. 15/875,478 · Granted Oct 30, 2018

Heterocyclic compounds for the treatment of neurological and psychological disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,112,903
App. No.
15/875,478
Granted
Oct 30, 2018
Kind
B2
Abstract

Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

Claims (27)

1. A compound having the formula:

or a pharmaceutically acceptable salt or solvate thereof.

2. A compound having the formula:

3. A pharmaceutical composition comprising the compound of claim 1 , and one or more pharmaceutically acceptable carriers or excipients.

4. A pharmaceutical composition comprising the compound of claim 2 , and one or more pharmaceutically acceptable carriers or excipients.

5. A method of treating schizophrenia comprising administering the compound of claim 1 to a patient in need thereof.

6. A method of treating bipolar disorder comprising administering the compound of claim 1 to a patient in need thereof.

7. A method of treating depression comprising administering the compound of claim 1 to a patient in need thereof.

8. A method of treating mania comprising administering the compound of claim 1 to a patient in need thereof.

9. A method of treating anxiety comprising administering the compound of claim 1 to a patient in need thereof.

10. A method of treating schizophrenia comprising administering a compound having the formula:

to a patient in need thereof.

11. A method of treating bipolar disorder comprising administering a compound having the formula:

to a patient in need thereof.

12. A method of treating depression comprising administering the compound of claim 2 to a patient in need thereof.

13. A method of treating mania comprising administering the compound of claim 2 to a patient in need thereof.

14. A method of treating anxiety comprising administering the compound of claim 2 to a patient in need thereof.

15. A method of treating schizophrenia comprising administering the pharmaceutical composition of claim 3 to a patient in need thereof.

16. A method of treating bipolar disorder comprising administering the pharmaceutical composition of claim 3 to a patient in need thereof.

17. A method of treating depression comprising administering the pharmaceutical composition of claim 3 to a patient in need thereof.

18. A method of treating mania comprising administering the pharmaceutical composition of claim 3 to a patient in need thereof.

19. A method of treating anxiety comprising administering the pharmaceutical composition of claim 3 to a patient in need thereof.

20. A method of treating schizophrenia comprising administering the pharmaceutical composition of claim 4 to a patient in need thereof.

21. A method of treating bipolar disorder comprising administering the pharmaceutical composition of claim 4 to a patient in need thereof.

22. A method of treating depression comprising administering the pharmaceutical composition of claim 4 to a patient in need thereof.

23. A method of treating mania comprising administering the pharmaceutical composition of claim 4 to a patient in need thereof.

24. A method of treating anxiety comprising administering the pharmaceutical composition of claim 4 to a patient in need thereof.

Assignments (7)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE FROM ASSIGNMENT TO SECURITY AGREEMENT PREVIOUSLY RECORDED ON REEL 045315 FRAME 0812. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Mar 29, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 045789/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 045315/0812 →